

Philip Jonsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3131408/publications.pdf>

Version: 2024-02-01

47
papers

9,400
citations

126907

33
h-index

189892

50
g-index

50
all docs

50
docs citations

50
times ranked

17771
citing authors

#	ARTICLE	IF	CITATIONS
1	Anatomic position determines oncogenic specificity in melanoma. <i>Nature</i> , 2022, 604, 354-361.	27.8	44
2	The context-specific role of germline pathogenicity in tumorigenesis. <i>Nature Genetics</i> , 2021, 53, 1577-1585.	21.4	44
3	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. <i>JCO Precision Oncology</i> , 2020, 4, 1350-1360.	3.0	18
4	Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions. <i>Acta Neuropathologica Communications</i> , 2020, 8, 186.	5.2	26
5	Phase and context shape the function of composite oncogenic mutations. <i>Nature</i> , 2020, 582, 100-103.	27.8	31
6	Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2025-2037.	7.2	27
7	Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. <i>Oncologist</i> , 2020, 25, e68-e74.	3.7	10
8	A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1796-1802.	7.0	8
9	Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas. <i>Brain Pathology</i> , 2020, 30, 653-660.	4.1	3
10	Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 355-362.	5.3	11
11	Tumour lineage shapes BRCA-mediated phenotypes. <i>Nature</i> , 2019, 571, 576-579.	27.8	295
12	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 5537-5547.	7.0	107
13	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 471.	7.1	426
14	Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. <i>ELife</i> , 2019, 8, .	6.0	31
15	Transforming Biomarker Development with Exceptional Responders. <i>Trends in Cancer</i> , 2018, 4, 3-6.	7.4	2
16	Accelerating Discovery of Functional Mutant Alleles in Cancer. <i>Cancer Discovery</i> , 2018, 8, 174-183.	9.4	275
17	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2018, 4, 986-994.	3.1	29
18	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. <i>Cancer Discovery</i> , 2018, 8, 49-58.	9.4	275

#	ARTICLE	IF	CITATIONS
19	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-641.	1.6	1,109
20	Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3925-3930.	3.6	106
21	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. <i>Cancer Cell</i> , 2018, 34, 852-862.e4.	16.8	73
22	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018, 34, 427-438.e6.	16.8	633
23	Genome doubling shapes the evolution and prognosis of advanced cancers. <i>Nature Genetics</i> , 2018, 50, 1189-1195.	21.4	411
24	A Secondary Mutation in <i>BRAF</i> Confers Resistance to RAF Inhibition in a <i>BRAF</i> V600E-Mutant Brain Tumor. <i>Cancer Discovery</i> , 2018, 8, 1130-1141.	9.4	56
25	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473
26	Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. <i>Neuro-Oncology</i> , 2017, 19, 1380-1390.	1.2	35
27	Insufficient antibody validation challenges oestrogen receptor beta research. <i>Nature Communications</i> , 2017, 8, 15840.	12.8	170
28	A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. <i>Cancer Discovery</i> , 2017, 7, 963-972.	9.4	331
29	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. <i>Cancer Discovery</i> , 2017, 7, 596-609.	9.4	490
30	Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression. <i>Autophagy</i> , 2017, 13, 506-521.	9.1	88
31	Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 735-748.	27.6	234
32	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. <i>Cell Stem Cell</i> , 2017, 21, 374-382.e4.	11.1	578
33	AP-1 Is a Key Regulator of Proinflammatory Cytokine TNF α -mediated Triple-negative Breast Cancer Progression. <i>Journal of Biological Chemistry</i> , 2016, 291, 5068-5079.	3.4	85
34	Lxr regulates lipid metabolic and visual perception pathways during zebrafish development. <i>Molecular and Cellular Endocrinology</i> , 2016, 419, 29-43.	3.2	30
35	RING finger protein 31 promotes p53 degradation in breast cancer cells. <i>Oncogene</i> , 2016, 35, 1955-1964.	5.9	58
36	AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNF α -induced epithelial-mesenchymal transition in triple-negative breast cancer. <i>Oncotarget</i> , 2015, 6, 7804-7814.	1.8	48

#	ARTICLE	IF	CITATIONS
37	Estrogen Receptor β Induces Hypoxia Signature of Gene Expression by Stabilizing HIF-1 α in Prostate Cancer. <i>PLoS ONE</i> , 2015, 10, e0128239.	2.5	33
38	Single-Molecule Sequencing Reveals Estrogen-Regulated Clinically Relevant lncRNAs in Breast Cancer. <i>Molecular Endocrinology</i> , 2015, 29, 1634-1645.	3.7	56
39	Coexposure to Phytoestrogens and Bisphenol A Mimics Estrogenic Effects in an Additive Manner. <i>Toxicological Sciences</i> , 2014, 138, 21-35.	3.1	50
40	Support of a bi-faceted role of estrogen receptor β (ER β) in ER α -positive breast cancer cells. <i>Endocrine-Related Cancer</i> , 2014, 21, 143-160.	3.1	34
41	Genome-wide Profiling of AP-1-Regulated Transcription Provides Insights into the Invasiveness of Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2014, 74, 3983-3994.	0.9	103
42	miR-206 inhibits cell migration through direct targeting of the actin-binding protein Coronin 1C in triple-negative breast cancer. <i>Molecular Oncology</i> , 2014, 8, 1690-1702.	4.6	77
43	Interplay between AP-1 and estrogen receptor α in regulating gene expression and proliferation networks in breast cancer cells. <i>Carcinogenesis</i> , 2012, 33, 1684-1691.	2.8	51
44	Estrogen Receptors β 1 and β 2 Have Opposing Roles in Regulating Proliferation and Bone Metastasis Genes in the Prostate Cancer Cell Line PC3. <i>Molecular Endocrinology</i> , 2012, 26, 1991-2003.	3.7	99
45	Knockdown of SF-1 and RNF31 Affects Components of Steroidogenesis, TGF β , and Wnt/ β -catenin Signaling in Adrenocortical Carcinoma Cells. <i>PLoS ONE</i> , 2012, 7, e32080.	2.5	24
46	Estrogen Receptor β Induces Antiinflammatory and Antitumorigenic Networks in Colon Cancer Cells. <i>Molecular Endocrinology</i> , 2011, 25, 969-979.	3.7	98
47	The Two-Pore Domain Potassium Channel KCNK5: Induction by Estrogen Receptor α and Role in Proliferation of Breast Cancer Cells. <i>Molecular Endocrinology</i> , 2011, 25, 1326-1336.	3.7	51